MX341324B - Polipeptidos. - Google Patents
Polipeptidos.Info
- Publication number
- MX341324B MX341324B MX2013013913A MX2013013913A MX341324B MX 341324 B MX341324 B MX 341324B MX 2013013913 A MX2013013913 A MX 2013013913A MX 2013013913 A MX2013013913 A MX 2013013913A MX 341324 B MX341324 B MX 341324B
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- pramlintide
- medicaments
- analogue
- amino acid
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical class C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57527—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
Abstract
La presente invención se refiere a polipéptidos que comprenden una secuencia de aminoácidos que es un análogo de pramlintide, composiciones farmacéuticas que comprenden estos polipéptidos, y estos polipéptidos para usarse como medicamentos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169405 | 2011-06-10 | ||
| US201161496113P | 2011-06-13 | 2011-06-13 | |
| PCT/EP2012/060900 WO2012168432A1 (en) | 2011-06-10 | 2012-06-08 | Polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013013913A MX2013013913A (es) | 2013-12-16 |
| MX341324B true MX341324B (es) | 2016-08-16 |
Family
ID=47295518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013913A MX341324B (es) | 2011-06-10 | 2012-06-08 | Polipeptidos. |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8722849B2 (es) |
| EP (3) | EP2718315B1 (es) |
| JP (3) | JP6247205B2 (es) |
| KR (1) | KR102066987B1 (es) |
| CN (3) | CN103596973A (es) |
| AU (1) | AU2012266269B2 (es) |
| BR (1) | BR112013031268B1 (es) |
| CA (1) | CA2838884C (es) |
| ES (1) | ES2664509T3 (es) |
| IL (1) | IL229258B (es) |
| MX (1) | MX341324B (es) |
| MY (1) | MY161773A (es) |
| PL (1) | PL2718316T3 (es) |
| RS (1) | RS59977B1 (es) |
| RU (1) | RU2669999C2 (es) |
| SI (1) | SI2718316T1 (es) |
| WO (3) | WO2012168431A2 (es) |
| ZA (1) | ZA201309174B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8722849B2 (en) * | 2011-06-10 | 2014-05-13 | Novo Nordisk A/S | Polypeptides |
| US8575091B1 (en) * | 2012-04-19 | 2013-11-05 | Novo Nordisk A/S | Amylin analogues and pharmaceutical compositions thereof |
| MA38472B1 (fr) | 2013-05-28 | 2018-09-28 | Takeda Pharmaceuticals Co | Composé peptidique |
| AR097701A1 (es) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| JP6728141B2 (ja) * | 2014-09-04 | 2020-07-22 | ノヴォ ノルディスク アー／エス | 新規のアミリン及びカルシトニン受容体アゴニスト |
| JP2018012644A (ja) * | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
| CN105985995A (zh) * | 2015-01-29 | 2016-10-05 | 暨南大学 | 一种利用家蚕生物反应器生产普兰林肽(pa)的方法 |
| EP3271381B1 (en) * | 2015-03-18 | 2021-09-08 | Zealand Pharma A/S | Amylin analogues |
| CN106554405B (zh) * | 2015-09-30 | 2020-04-24 | 深圳翰宇药业股份有限公司 | 一种多肽及其用途、制备方法 |
| CN106928086B (zh) * | 2015-12-31 | 2019-05-31 | 深圳翰宇药业股份有限公司 | 一种长链化合物的制备方法 |
| EP3467106A4 (en) | 2016-05-24 | 2020-02-26 | Takeda Pharmaceutical Company Limited | PEPTIDE COMPOUND |
| US10071140B2 (en) | 2016-09-09 | 2018-09-11 | Zealand Pharma A/S | Amylin analogues |
| JP7076442B2 (ja) | 2016-11-07 | 2022-05-27 | ノヴォ ノルディスク アー／エス | Ｐｅｇ化合物のｄｃｈｂｓ活性エステル及びその使用 |
| MX2020001525A (es) | 2017-08-24 | 2020-03-20 | Novo Nordisk As | Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos. |
| AR116632A1 (es) | 2018-10-11 | 2021-05-26 | Intarcia Therapeutics Inc | Polipéptidos análogos de la amilina humana y sus métodos de uso |
| US20220226488A1 (en) | 2019-02-12 | 2022-07-21 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
| EP3927725A4 (en) * | 2019-02-22 | 2023-06-14 | Loyola Marymount University | AMYLOID PEPTIDE VARIANTS |
| WO2021094259A1 (en) | 2019-11-11 | 2021-05-20 | Boehringer Ingelheim International Gmbh | Npy2 receptor agonists |
| US20230093542A1 (en) | 2020-02-18 | 2023-03-23 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| BR112022025623A2 (pt) | 2020-08-07 | 2023-03-07 | Boehringer Ingelheim Int | Agonistas solúveis de receptores de npy2 |
| WO2022040596A1 (en) | 2020-08-20 | 2022-02-24 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
| KR20230073176A (ko) | 2020-09-24 | 2023-05-25 | 구브라 에이피에스 | 개선된 아밀린 수용체(hAMY3R) 효능을 갖는 HAM15-52 유사체 |
| IL303127A (en) | 2020-12-18 | 2023-07-01 | Novo Nordisk As | GLP-1 and amylin receptor co-agonists |
| TWI815327B (zh) * | 2021-03-03 | 2023-09-11 | 美商美國禮來大藥廠 | 長效澱粉素受體促效劑及其用途 |
| EP4313163A1 (en) | 2021-04-03 | 2024-02-07 | Ambrx, Inc. | Anti-her2 antibody-drug conjugates and uses thereof |
| EP4144362A1 (en) | 2021-09-06 | 2023-03-08 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
| WO2022248419A2 (en) | 2021-05-22 | 2022-12-01 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
| EP4129324A1 (en) | 2021-08-02 | 2023-02-08 | Adocia | Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist |
| TW202339788A (zh) | 2021-12-13 | 2023-10-16 | 丹麥商諾佛 儂迪克股份有限公司 | 包括環糊精的醫藥調配物 |
| WO2023187067A1 (en) | 2022-03-30 | 2023-10-05 | Novo Nordisk A/S | Formulation method |
| WO2023227133A1 (zh) * | 2022-05-27 | 2023-11-30 | 杭州先为达生物科技股份有限公司 | 人胰淀素类似物、其衍生物及用途 |
| WO2024061919A1 (en) | 2022-09-19 | 2024-03-28 | Zealand Pharma A/S | Combination therapy |
| WO2024133739A1 (en) | 2022-12-22 | 2024-06-27 | Novo Nordisk A/S | Amylin receptor agonists |
| WO2024164776A1 (zh) * | 2023-02-10 | 2024-08-15 | 杭州先为达生物科技股份有限公司 | 多肽及其衍生物、组合物及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA936811B (en) * | 1992-10-28 | 1995-03-15 | Upjohn Co | Somatotropin modifications |
| US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| ATE491723T1 (de) | 1998-02-13 | 2011-01-15 | Amylin Pharmaceuticals Inc | Neue verbindungen mit gemischter amylin aktivität |
| WO1999057147A1 (fr) * | 1998-04-30 | 1999-11-11 | Kirin Brewery Company, Limited | Mutants de la thrombopoietine humaine |
| WO2000006724A1 (fr) * | 1998-07-31 | 2000-02-10 | Kirin Beer Kabushiki Kaisha | Medicaments permettant de soigner la neuropathie contenant de la galectine-1 ou ses derives comme substance active |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP1730186A2 (en) * | 2004-03-31 | 2006-12-13 | Xencor, Inc. | Bmp-7 variants with improved properties |
| WO2007104789A2 (en) | 2006-03-15 | 2007-09-20 | Novo Nordisk A/S | Amylin derivatives |
| CN101578102B (zh) * | 2007-01-05 | 2013-07-17 | 印第安纳大学研究及科技有限公司 | 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物 |
| EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| US20110152183A1 (en) | 2008-06-25 | 2011-06-23 | Novo Nordisk A/S | Derivatised hybrid peptides of amylin and salmon calcitonin |
| EP2340261B1 (en) | 2008-10-21 | 2017-12-20 | Novo Nordisk A/S | Amylin derivatives |
| JP5850848B2 (ja) * | 2009-11-25 | 2016-02-03 | ノヴォ ノルディスク アー／エス | ポリペプチドの製造方法 |
| US8722849B2 (en) * | 2011-06-10 | 2014-05-13 | Novo Nordisk A/S | Polypeptides |
-
2012
- 2012-06-08 US US13/491,885 patent/US8722849B2/en active Active
- 2012-06-08 PL PL12729418T patent/PL2718316T3/pl unknown
- 2012-06-08 JP JP2014514092A patent/JP6247205B2/ja active Active
- 2012-06-08 KR KR1020137034732A patent/KR102066987B1/ko active IP Right Grant
- 2012-06-08 US US13/491,880 patent/US8575090B2/en active Active
- 2012-06-08 JP JP2014514090A patent/JP2014519509A/ja active Pending
- 2012-06-08 CN CN201280028644.0A patent/CN103596973A/zh active Pending
- 2012-06-08 EP EP12729417.1A patent/EP2718315B1/en active Active
- 2012-06-08 RS RS20200191A patent/RS59977B1/sr unknown
- 2012-06-08 BR BR112013031268-8A patent/BR112013031268B1/pt active IP Right Grant
- 2012-06-08 WO PCT/EP2012/060899 patent/WO2012168431A2/en active Application Filing
- 2012-06-08 US US13/491,883 patent/US8741836B2/en active Active
- 2012-06-08 RU RU2013156937A patent/RU2669999C2/ru active
- 2012-06-08 MY MYPI2013004133A patent/MY161773A/en unknown
- 2012-06-08 WO PCT/EP2012/060897 patent/WO2012168430A2/en active Application Filing
- 2012-06-08 CA CA2838884A patent/CA2838884C/en active Active
- 2012-06-08 CN CN201280028642.1A patent/CN103649115B/zh active Active
- 2012-06-08 ES ES12729417.1T patent/ES2664509T3/es active Active
- 2012-06-08 JP JP2014514091A patent/JP6121992B2/ja active Active
- 2012-06-08 CN CN201280028554.1A patent/CN103596972B/zh active Active
- 2012-06-08 EP EP12729416.3A patent/EP2718314A2/en not_active Withdrawn
- 2012-06-08 AU AU2012266269A patent/AU2012266269B2/en active Active
- 2012-06-08 SI SI201231728T patent/SI2718316T1/sl unknown
- 2012-06-08 WO PCT/EP2012/060900 patent/WO2012168432A1/en active Application Filing
- 2012-06-08 EP EP12729418.9A patent/EP2718316B1/en active Active
- 2012-06-08 MX MX2013013913A patent/MX341324B/es active IP Right Grant
-
2013
- 2013-09-26 US US14/038,265 patent/US9029325B2/en active Active
- 2013-11-05 IL IL22925813A patent/IL229258B/en active IP Right Grant
- 2013-12-05 ZA ZA2013/09174A patent/ZA201309174B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX341324B (es) | Polipeptidos. | |
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| MX2012007806A (es) | Composiciones farmaceuticas para administracion oral de peptidos de insulina. | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| JO3357B1 (ar) | مركبات إيميدازوبيروليدينون | |
| PH12015501609A1 (en) | Phenicol antibacterials | |
| PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| MX349004B (es) | Nuevos compuestos. | |
| MX2013000958A (es) | Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma. | |
| GEP201706621B (en) | Benzamides | |
| MX362879B (es) | Usos novedosos. | |
| PH12016501686A1 (en) | Pharmaceutical compositions of sitagliptin | |
| MX340983B (es) | Composiciones farmaceuticas y nutraceuticas de acido abscisico. | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| PH12017500089B1 (en) | Aldosterone synthase inhibitors | |
| UA113540C2 (xx) | Поліморфи n-(2-метоксибензоїл)-4-$(метиламінокарбоніл)аміно]бензолсульфонаміду | |
| IN2014DN03010A (es) | ||
| SG10201808383UA (en) | Cyclic apelin analogs | |
| MX2014004742A (es) | Nuevos agentes antibacterianos de fenicol. | |
| TR201106224A2 (tr) | Solunum yolu hastalıkları tedavisinde kullanılan farmasötik bileşimler. | |
| IN2013MU02279A (es) | ||
| UA110793C2 (uk) | Піразолілхіноксалінові інгібітори кінази |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |